Botulinum Toxin in the Treatment of Headache

Botulinum toxin type A has been used in the treatment of chronic migraine for over a decade and has become established as a well-tolerated option for the preventive therapy of chronic migraine. Ongoing research is gradually shedding light on its mechanism of action in migraine prevention. Given that...

Full description

Saved in:
Bibliographic Details
Published in:Toxins 2020-12, Vol.12 (12), p.803
Main Author: Becker, Werner J
Format: Article
Language:English
Subjects:
Botulinum toxin
Botulinum toxin type A
Calcitonin
Calcitonin gene-related peptide
CGRP
chronic migraine
Clinical trials
Deoxyribonucleic acid
DNA
erenumab
FDA approval
Headache
Headaches
Migraine
Monoclonal antibodies
onabotulinumtoxinA
Patients
Recombinant DNA
Review
Sensory neurons
Strabismus
Toxins
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Botulinum toxin type A has been used in the treatment of chronic migraine for over a decade and has become established as a well-tolerated option for the preventive therapy of chronic migraine. Ongoing research is gradually shedding light on its mechanism of action in migraine prevention. Given that its mechanism of action is quite different from that of the new monoclonal antibodies directed against calcitonin gene-related peptide (CGRP) or its receptor, it is unlikely to be displaced to any major extent by them. Both will likely remain as important tools for patients with chronic migraine and the clinicians assisting them. New types of botulinum toxin selective for sensory pain neurons may well be discovered or produced by recombinant DNA techniques in the coming decade, and this may greatly enhance its therapeutic usefulness. This review summarizes the evolution of botulinum toxin use in headache management over the past several decades and its role in the preventive treatment of chronic migraine and other headache disorders.
ISSN:2072-6651
2072-6651
DOI:10.3390/toxins12120803